Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine
- PMID: 16603620
- PMCID: PMC1459635
- DOI: 10.1128/CVI.13.4.507-510.2006
Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine
Abstract
Changes in the immunoglobulin G1 (IgG1)/IgG2 ratio following vaccination can indicate the activation of cellular control mechanisms typical of a T-cell-dependent response. We examined IgG subclass ratios in 17 healthy adults (26 to 55 years of age) before and 4 to 6 weeks following immunization with a quadrivalent meningococcal-polysaccharide diphtheria toxoid conjugate vaccine against serogroups A, C, Y, and W135. Serologic responses were determined by serum bactericidal antibody assay and serogroup-specific IgG, IgG1, and IgG2 enzyme-linked immunosorbent assay. Prevaccination serogroup A-specific IgG1/IgG2 ratios were <1 for all subjects and differed by subject for C, Y, and W-135. Postvaccination, significant increases in IgG, IgG1, and IgG2, were observed for all serogroups. Serogroup-specific IgG1/IgG2 ratios increased for group A (14/17 subjects, 88%), decreased in more than half of subjects for groups C (9/17, 53%) and W135 (12/17, 71%) and decreased for serogroup Y (16/17, 94%). IgG1/IgG2 ratios differed between individual vaccinees and were similar to the responses of adults who received pneumococcal conjugate vaccines or a monovalent C conjugate vaccine. Further studies on IgG subclasses following meningococcal polysaccharide and conjugate vaccination are needed.
Figures
Similar articles
-
Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.Vaccine. 2016 Oct 17;34(44):5273-5278. doi: 10.1016/j.vaccine.2016.09.003. Epub 2016 Sep 15. Vaccine. 2016. PMID: 27642132 Clinical Trial.
-
Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera.Clin Diagn Lab Immunol. 2004 Jan;11(1):1-5. doi: 10.1128/cdli.11.1.1-5.2004. Clin Diagn Lab Immunol. 2004. PMID: 14715537 Free PMC article.
-
Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children.Pediatr Infect Dis J. 2005 Jan;24(1):57-62. doi: 10.1097/01.inf.0000148928.10057.86. Pediatr Infect Dis J. 2005. PMID: 15665711 Clinical Trial.
-
MenACWY-TT vaccine for active immunization against invasive meningococcal disease.Expert Rev Vaccines. 2012 May;11(5):523-37. doi: 10.1586/erv.12.32. Expert Rev Vaccines. 2012. PMID: 22827239 Review.
-
Prospects for vaccine prevention of meningococcal infection.Clin Microbiol Rev. 2006 Jan;19(1):142-64. doi: 10.1128/CMR.19.1.142-164.2006. Clin Microbiol Rev. 2006. PMID: 16418528 Free PMC article. Review.
Cited by
-
Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals.Front Immunol. 2021 Oct 8;12:747594. doi: 10.3389/fimmu.2021.747594. eCollection 2021. Front Immunol. 2021. PMID: 34691058 Free PMC article.
-
Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants.Vaccine. 2019 Apr 24;37(18):2477-2481. doi: 10.1016/j.vaccine.2019.03.045. Epub 2019 Apr 2. Vaccine. 2019. PMID: 30952500 Free PMC article. Clinical Trial.
-
Meningococcal vaccination in pregnancy.Hum Vaccin Immunother. 2018 May 4;14(5):1188-1196. doi: 10.1080/21645515.2018.1445447. Epub 2018 Mar 21. Hum Vaccin Immunother. 2018. PMID: 29485347 Free PMC article. Review.
-
Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults.Front Immunol. 2017 Jul 19;8:817. doi: 10.3389/fimmu.2017.00817. eCollection 2017. Front Immunol. 2017. PMID: 28769927 Free PMC article.
-
High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.Genome Med. 2017 Jan 30;9(1):11. doi: 10.1186/s13073-017-0400-x. Genome Med. 2017. PMID: 28137280 Free PMC article.
References
-
- Bilukha, O. O., and N. E. Rosenstein. 2005. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 54:1-21. - PubMed
-
- Campbell, J. D., R. Edelman, J. C. King, Jr., T. Papa, R. Ryall, and M. B. Rennels. 2002. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J. Infect. Dis. 186:1848-1851. - PubMed
-
- Carlone, G. M., C. E. Frasch, G. R. Siber, S. Quataert, L. L. Gheesling, S.H.Turner, B. D. Pilkaytis, L. O. Helsel, W. E. DeWitt, W. F. Bibb, B. Swaminthan, G. Arakere, C. Thompson, D. Phipps, D. Madore, and C. V. Broome. 1992. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A polysaccharide measured by using an enzyme-linked immunosorbent assay. J. Clin. Microbiol. 30:154-159. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
